市場調査レポート
商品コード
1562248

北米の感染症治療薬：2030年市場予測- 地域別分析- 薬剤クラス別、適応症別、投与経路別、流通経路別

North America Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration, and Distribution Channel
表紙：北米の感染症治療薬：2030年市場予測- 地域別分析- 薬剤クラス別、適応症別、投与経路別、流通経路別

出版日
ページ情報
英文 100 Pages
納期
即納可能
北米の感染症治療薬：2030年市場予測- 地域別分析- 薬剤クラス別、適応症別、投与経路別、流通経路別
出版日: 2024年07月04日
発行: The Insight Partners
ページ情報: 英文 100 Pages
納期: 即納可能
GIIご利用のメリット

  • 全表示

  • 概要
  • 図表
  • 目次
概要

北米の感染症治療薬市場は、2022年に463億7,653万米ドルと評価され、2030年には659億5,597万米ドルに達すると予測され、2022年から2030年までのCAGRは4.5%と推定されます。

感染症の流行が北米の感染症治療薬市場を後押し

感染症は、ウイルス、寄生虫、細菌、真菌、毒性産物、その他の感染因子によって引き起こされます。HIVは世界中で公衆衛生上の大きな問題となっています。国連合同エイズ計画（UNAIDS）によると、2020年には3,770万人がHIVに感染しています。このうち3,600万人が成人で、0～14歳の子どもが170万人です。また、半数以上（53％）が少女と女性です。さらに、2020年には世界で新たに150万人のHIV感染者が報告されました。同様に、肝炎はウイルス感染によって引き起こされる肝臓の感染症です。世界保健機関（WHO）によると、世界では5,800万人がC型慢性肝炎ウイルスに感染しており、毎年150万人が新たに感染しています。

WHOによると、結核は世界第13位の死因であり、COVID-19に次いで第2位の感染症です。2020年には、結核が原因で150万人が死亡しました（HIV感染者21万4,000人を含む）。さらに、2020年には世界で1,000万人が結核に罹患し、そのうち110万人が子ども、330万人が女性、560万人が男性です。さらに、院内感染やヘルスケア関連感染（HAI）は、罹患率や死亡率が高いです。また、ヘルスケアシステムへの支出は毎年巨額にのぼります。米国疾病予防管理センター（CDC）の報告によると、アメリカの病院では毎年170万件の感染症例と99,000人の死亡がHAIによって引き起こされています。したがって、世界中で感染症の流行が増加していることが、感染症治療薬市場の成長を後押ししています。

北米の感染症治療薬市場概要

北米の感染症治療薬市場は、米国、カナダ、メキシコに区分されます。北米は2022年の世界市場で最大のシェアを占めています。技術進歩の市場開拓と研究開発の活発化が、感染症治療薬市場の成長を加速すると予測されています。さらに、大規模なヘルスケア事業と、慢性疾患やウイルス性疾患を治療するための高度な治療ソリューションに対する需要の高まりが、この地域での市場拡大を後押ししています。抗ウイルス療法の採用拡大による抗ウイルス剤に対する需要の急増は、米国の市場を牽引すると予想されます。主要な医薬品・バイオ医薬品企業は、抗ウイルス剤の製造能力の拡大に注力しています。例えば、Gilead Sciences, Inc.（カリフォルニア州）は、2020年5月にCOVID-19治療用の治験用抗ウイルス剤-レムデシビルのFDA承認を取得しました。さらに2022年4月、米国食品医薬品局（FDA）はGilead Sciences, Inc.のベクルーリー（レムデシビル）について、生後28日以上、体重3kg以上で、COVID-19治療のために入院中の小児患者、または軽度から中等度のCOVID-19感染症の治療に対する追加新薬承認申請（sNDA）を承認しました。2021年9月、バイデン-ハリス政権は、国内の公衆衛生およびヘルスケア部門全体の感染制御および予防活動を改善するため、疾病対策予防センター（CDC）を通じて21億米ドルを投資しました。これらの要因が、予測期間中の米国感染症治療薬市場の成長を後押しすると予想されます。

北米の感染症治療薬市場の収益と2030年までの予測（金額）

北米の感染症治療薬市場セグメンテーション

北米の感染症治療薬市場は、薬剤クラス別、適応症別、投与経路別、流通チャネル別、国別に分類されます。

薬剤クラス別では、北米の感染症治療薬市場は抗ウイルス薬、抗細菌薬、抗真菌薬、その他に区分されます。2022年の市場シェアは抗ウイルス剤が最大でした。

適応症の観点から、北米の感染症治療薬市場はHIV、肝炎、結核、インフルエンザ、HPV、その他に区分されます。2022年にはHIVが最大の市場シェアを占めています。

投与経路に基づき、北米の感染症治療薬市場は経口剤、非経口剤、局所剤、その他に区分されます。2022年には経口剤が最大の市場シェアを占めています。

流通チャネルでは、北米の感染症治療薬市場は病院薬局、小売薬局、その他に区分されます。2022年には病院薬局が最大の市場シェアを占めました。

国別では、北米の感染症治療薬市場は米国、カナダ、メキシコに区分されます。2022年の北米の感染症治療薬市場シェアは米国が独占しました。

AbbVie Inc、Astellas Pharma Inc、Bayer AG、BioCryst Pharmaceuticals Inc、F. Hoffmann-La Roche Ltd、Gilead Sciences Inc、GSK Plc、Merck &Co Inc、Pfizer Inc、Shionogi &Co Ltdは、北米の感染症治療薬市場で事業を展開する主要企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 北米の感染症治療薬市場- 主要市場力学

  • 北米の感染症治療薬市場：主要市場力学
  • 市場促進要因
    • 感染症の有病率の上昇
    • 感染症治療薬の資金調達と研究開発への注目の高まり
  • 市場抑制要因
    • 抗感染症薬の耐性とそれに伴う副作用の出現
  • 市場機会
    • 発展途上国における成長機会
    • 抗生物質耐性の脅威の高まり
  • 今後の動向
    • 承認・上市数の増加
  • 促進要因と抑制要因の影響

第5章 感染症治療薬市場：北米市場分析

  • 北米の感染症治療薬市場収益、2022年～2030年

第6章 北米の感染症治療薬市場分析：薬剤クラス別

  • 抗ウイルス剤
  • 抗細菌薬
  • 抗真菌薬
  • その他

第7章 北米の感染症治療薬市場分析：適応症別

  • HIV
  • 肝炎
  • 結核
  • インフルエンザ
  • HPV
  • その他

第8章 北米の感染症治療薬市場分析：投与経路別

  • 経口
  • 非経口
  • 局所
  • その他

第9章 北米の感染症治療薬市場分析：流通チャネル別

  • 病院薬局
  • 小売薬局
  • その他

第10章 北米の感染症治療薬市場：国別分析

  • 米国
  • カナダ
  • メキシコ

第11章 感染症治療薬市場：業界情勢

  • 感染症治療薬市場における成長戦略
  • 無機的成長戦略
  • 有機的成長戦略

第12章 企業プロファイル

  • Pfizer Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Shionogi & Co Ltd
  • Bayer AG
  • BioCryst Pharmaceuticals Inc
  • GSK Plc
  • AbbVie Inc
  • Merck & Co Inc
  • Astellas Pharma Inc

第13章 付録

図表

List Of Tables

  • Table 1. North America Infectious Disease Therapeutics Market Segmentation
  • Table 2. Diseases and Funding
  • Table 3. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
  • Table 4. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
  • Table 5. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 6. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 7. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 8. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 9. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 10. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 11. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 12. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 13. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 14. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 15. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 16. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 17. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 18. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 19. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 20. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
  • Table 21. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List Of Figures

  • Figure 1. North America Infectious Disease Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
  • Figure 4. North America Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
  • Figure 5. Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. North America Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
  • Figure 10. HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. North America Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
  • Figure 17. Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. North America Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. North America Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. North America Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Growth Strategies in the Infectious Disease Therapeutics Market
目次
Product Code: BMIRE00030503

The North America infectious disease therapeutics market was valued at US$ 46,376.53 million in 2022 and is expected to reach US$ 65,955.97 million by 2030; it is estimated to register a CAGR of 4.5% from 2022 to 2030.

Rising Prevalence of Infectious Disease Fuels North America Infectious Disease Therapeutics Market

Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0-14 years. Also, more than half (53%) were girls and women. Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.

According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. The Centers for Disease Control and Prevention (CDC) reported that HAIs account for ~1.7 million infection cases and 99,000 deaths every year in American hospitals. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market.

North America Infectious Disease Therapeutics Market Overview

The infectious disease therapeutics market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the global market in 2022. Growing adoption of technological advancements and rising research and development activities are projected to accelerate the growth of the infectious disease therapeutics market. Moreover, large healthcare businesses and the rising demand for advanced therapeutic solutions to treat chronic conditions and viral diseases are propelling the market expansion in this region. The burgeoning demand for antiviral agents due to the growing adoption of antiviral therapies is anticipated to drive the market in the US. Major medicine and biopharmaceutical companies focus on expanding their antiviral agent manufacturing capacities. For instance, Gilead Sciences, Inc., California, received FDA approval for its investigational antiviral-Remdesivir-to treat COVID-19 in May 2020. Additionally, in April 2022, the US Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) of Gilead Sciences for Veklury (remdesivir) for the treatment of pediatric patients above 28 days, weighing at least 3 kg, and are hospitalized for COVID-19 treatment or have mild-to-moderate COVID-19 infection. In September 2021, the Biden-Harris Administration invested US$ 2.1 billion through the Centers for Disease Control and Prevention (CDC) to improve infection control and prevention activities across the country's public health and healthcare sectors. These factors are anticipated to boost the US infectious disease therapeutics market growth during the forecast period.

North America Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

North America Infectious Disease Therapeutics Market Segmentation

The North America infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the North America infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the North America infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the North America infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the North America infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the North America infectious disease therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the North America infectious disease therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Infectious Disease Therapeutics Market - Key Market Dynamics

  • 4.1 North America Infectious Disease Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Infectious Disease
    • 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
  • 4.4 Market Opportunities
    • 4.4.1 Growing Opportunities in Developing Nations
    • 4.4.2 Escalating Threat of Antibiotic Resistance
  • 4.5 Future Trends
    • 4.5.1 Rising Number of Product Approvals and Launches
  • 4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - North America Market Analysis

  • 5.1 North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. North America Infectious Disease Therapeutics Market Analysis - by Drug Class

  • 6.1 Overview
  • 6.2 Anti-Viral
    • 6.2.1 Overview
    • 6.2.2 Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Anti-bacterial
    • 6.3.1 Overview
    • 6.3.2 Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Anti-fungal
    • 6.4.1 Overview
    • 6.4.2 Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Infectious Disease Therapeutics Market Analysis - by Indication

  • 7.1 Overview
  • 7.2 HIV
    • 7.2.1 Overview
    • 7.2.2 HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Hepatitis
    • 7.3.1 Overview
    • 7.3.2 Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Tuberculosis
    • 7.4.1 Overview
    • 7.4.2 Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Influenza
    • 7.5.1 Overview
    • 7.5.2 Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 HPV
    • 7.6.1 Overview
    • 7.6.2 HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Infectious Disease Therapeutics Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Topical
    • 8.4.1 Overview
    • 8.4.2 Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Infectious Disease Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Retail Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Infectious Disease Therapeutics Market - Country Analysis

  • 10.1 North America Infectious Disease Therapeutics Market Overview
    • 10.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
      • 10.1.1.3 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 United States: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.3.2 United States: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.3.3 United States: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.3.4 United States: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.4 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
      • 10.1.1.5 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 Canada: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.5.2 Canada: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.5.3 Canada: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.5.4 Canada: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.6 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
      • 10.1.1.7 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.7.1 Mexico: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.7.2 Mexico: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.7.3 Mexico: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.7.4 Mexico: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Infectious Disease Therapeutics Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Pfizer Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Gilead Sciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 F. Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Shionogi & Co Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Bayer AG
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 BioCryst Pharmaceuticals Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 GSK Plc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 AbbVie Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Merck & Co Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Astellas Pharma Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners